Gentian Diagnostics ASA

Report Publication Announcement • Jun 18, 2021

Gentian Diagnostics: Invitation to virtual presentation at 24 June

Gentian Diagnostics: Invitation to virtual presentation at 24 June

Gentian Diagnostics ASA has the pleasure of inviting to a virtual presentation on Thursday 24 June 2021 at 10:00-11.00 am CEST in relation with the company’s updated investor presentation and new long-term ambition (see separate stock exchange release earlier today).

Gentian’s CEO Hilja Ibert, CSO Erling Sundrehagen and CFO Njaal Kind will present the company followed by a Q&A session.

Join the online presentation via the following link:

https: https://streams.eventcdn.net/gentian/company-presentation/

Questions can be submitted during the online webcast.

IR contact:

Njaal Kind, CFO

njaal.kind@gentian.no

+47 919 06 525 (mobile)

About Gentian Diagnostics

Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within immunochemistry, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China. For more information, please visit www.gentian.com.